RE:RE:RE:RE:RE:RE:Equity raise or LoCStockman, I was sad to see Moran and Gagnon and a large number of their respective teams leave the company. However, corporate presentations have indicated that the company has identified some 30 molecules/applications which will drive their future small molecule program. The next step for 4050, 4547 and others to be identified is to get them into clinical trials which are done in a rigorous and professional way (placebo controlled). The company has a new fellow who <br /> has a lot of experience in leading clinical trials and the trials themselves will likely be contracted out. I n my view the intention is to create value in the small molecule division with successful clinical trial results in a couple of applications and then sell it to the highest bidder. So in this sense I am ok with the downsizing of the scientific team. Let's see if the company get things right this time around. Unfortunately it is going to take time and money in a Covid uncertain world.